The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer

BACKGROUND: Activating mutations in RAS are present in the majority of pancreatic cancer cases and represent an ideal therapeutic target. Reolysin is a proprietary formulation of oncolytic reovirus that is currently being evaluated in multiple clinical trials due to its ability to selectively replic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahalingam, Devalingam, Patel, Sukeshi, Nuovo, Gerard, Gill, George, Selvaggi, Giovanni, Coffey, Matt, Nawrocki, Steffan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496814/
https://www.ncbi.nlm.nih.gov/pubmed/26156229
http://dx.doi.org/10.1186/s12885-015-1518-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496814/
https://www.ncbi.nlm.nih.gov/pubmed/26156229
http://dx.doi.org/10.1186/s12885-015-1518-0

Ejemplares similares